is an Associate at Bozicevic, Field & Francis LLP, where she practices patent prosecution and counseling, and her technical areas of expertise include biotechnology, molecular biology, gene therapy, immunology, and antibody engineering and therapeutics. Dr. Mahaseth earned her J.D. from Northwestern University School of Law (J.D., cum laude, 2018). Prior to law school, she received her Ph.D. (2015) and M.S. (2012) in Microbiology from the University of Illinois at Urbana-Champaign. Dr. Mahaseth received her Master of Science (2010) in Biological Sciences from Birla Institute of Technology and Science, Pilani with First Division honors.
Out of the 230 Orange Book patents challenged in IPR proceedings, 90.4% (208) of these patents were also challenged in Hatch-Waxman litigation perhaps due to the lucrative 180-day exclusivity incentive available to the first generic manufacturer to file a paragraph IV challenge when the Orange Book drug patent is successfully invalidated in a subsequent district court proceeding. Therefore, the IPR process has provided generic manufacturers a dual track option for challenging Orange Book patents by initiating Hatch-Waxman litigation and also pursuing IPRs. Overall, because the rate of settlement in IPRs is much lower than in Hatch-Waxman litigation, both generic manufacturers and patent owners obtain more favorable final decisions in IPRs as compared to their Hatch-Waxman litigation outcomes.